MATINS trial data presented at ESMO
Data from completed Part I of bexmarilimab MATINS trial presented at ESMO Virtual Congress 2020TURKU – FINLAND, 18 September 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announces details from an oral presentation being held at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, showcasing data from the Company’s ongoing MATINS trial to the scientific community. The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of bexmarilimab, Faron's wholly-owned novel